Personalis (PSNL)
NASDAQ:PSNL
Want to see PSNL full AI Analyst Report?
PSNL Stock Chart & Stats
$6.73
-$0.70(-11.71%)
At close: 4:00 PM EST
$6.73
-$0.70(-11.71%)
Day’s Range― - ―
52-Week Range$3.84 - $11.50
Previous CloseN/A
Volume738.16K
Average Volume (3M)2.34M
Market Cap
$886.99M
Enterprise Value$709.60M
Total Cash (Recent Filing)$233.22M
Total Debt (Recent Filing)$31.02M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 11, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding104,721,100
10 Day Avg. Volume2,783,335
30 Day Avg. Volume2,335,729
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-8.94
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue11.00
Enterprise Value/Gross Profit80.17
Enterprise Value/Ebitda-8.09
Forecast
1Y Price Target
$10.46Price Target Upside55.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.03
Revenue Forecast (FY)$78.89M
Bulls Say, Bears Say
Bulls Say
Biopharma Partnerships And Revenue PotentialRobust biopharma interest and guidance for biopharma business growth point to potential revenue upside and improved gross margins as pharma partnerships scale and drive testing demand.
Clinical Volume GrowthSharply rising clinical test volumes and dramatically higher annual test counts signal accelerating market demand and stronger commercial traction for the company's diagnostic services.
Reimbursement And Medicare CoverageMedicare coverage for surveillance of breast cancer and non-small cell lung cancer expands the number of major covered indications for the NeXT Personal test, reducing commercial risk and supporting clinical revenue growth.
Bears Say
Below-Consensus GuidanceGuidance for the coming year was provided below analyst consensus, creating downside pressure on growth expectations and the stock's outlook.
Margin And Cash Burn PressurePrioritizing rapid clinical adoption ahead of full reimbursement increases commercial spending, lowers near-term gross margins, and widens operating losses, raising near-term cash burn risk.
Revenue Concentration And CompetitionDeclines in pharmaceutical testing and population sequencing revenue, coupled with competitive pressure from a rival, underscore reliance on a limited set of revenue sources and elevate execution risk.
Personalis News
PSNL FAQ
What was Personalis’s price range in the past 12 months?
Personalis lowest stock price was $3.84 and its highest was $11.50 in the past 12 months.
What is Personalis’s market cap?
Personalis’s market cap is $886.99M.
When is Personalis’s upcoming earnings report date?
Personalis’s upcoming earnings report date is Aug 11, 2026 which is in 76 days.
How were Personalis’s earnings last quarter?
Personalis released its earnings results on May 07, 2026. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.271 by -$0.019.
Is Personalis overvalued?
According to Wall Street analysts Personalis’s price is currently Undervalued.
Does Personalis pay dividends?
Personalis does not currently pay dividends.
What is Personalis’s EPS estimate?
Personalis’s EPS estimate is -0.26.
How many shares outstanding does Personalis have?
Personalis has 104,721,100 shares outstanding.
What happened to Personalis’s price movement after its last earnings report?
Personalis reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.271. Following the earnings report the stock price went down -0.167%.
Which hedge fund is a major shareholder of Personalis?
Currently, no hedge funds are holding shares in PSNL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Personalis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.46 (55.47% Upside)
$10.46 (55.47% Upside)
Blogger Sentiment
Bearish
PSNL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 221.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
87.02%
12-Months-Change
Fundamentals
Return on Equity
-43.52%
Trailing 12-Months
Asset Growth
19.06%
Trailing 12-Months
Company Description
Personalis
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
PSNL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced strong operational and clinical momentum (rapid test volume growth, compelling real-world and study data, growing MRD pipeline, reimbursement wins and a healthy cash balance) against material near-term financial headwinds (severe gross margin compression, higher operating expenses, widening net loss and elevated cash burn). Management frames the negative margin and revenue mix trends as intentional investments to capture MRD market share and expects margins and ASPs to improve as reimbursed volume scales, but the timing of reimbursement and conversion to higher-margin revenue remains a key risk.View all PSNL earnings summariesPSNL Stock 12 Month Forecast
Average Price Target
$10.46
▲(55.47% Upside)
Technical Analysis
Ownership Overview
13.26% Insiders
14.39% Mutual Funds
50.41% Other Institutional Investors
7.58% Public Companies and
Individual Investors